Swine Vaccines Market – By Product (Inactivated, Live attenuated, Recombinant, Subunit Vaccines), Disease Type (Porcine Reproductive & Respiratory Syndrome, Porcine Circovirus Type 2, Mycoplasma Hyopneumoniae), End-user, Global Forecast 2024 – 2032

Swine Vaccines Market Size

Swine Vaccines Market size was valued at USD 1.6 billion in 2023 and is expected to exhibit growth at a CAGR of 5.3% from 2024 to 2032. The increasing prevalence of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and African Swine Fever (ASF) compels farmers to adopt vaccination programs to prevent devastating outbreaks. This surge in disease prevalence significantly drives the growth of the market.
 

Additionally, technological advancements in vaccine development, such as recombinant and DNA vaccines, enhance efficacy and safety, making them more appealing to swine producers and further fueling market growth. Furthermore, government initiatives and support for vaccination programs, coupled with improved veterinary services and distribution networks, facilitate market expansion. Additionally, heightened awareness about animal healthcare and welfare among farmers leads to greater vaccine adoption, reinforcing the market's upward trajectory.
 

Swine vaccines are immunological products designed to protect pigs from infectious diseases, enhancing their health, productivity, and welfare. These animal vaccines stimulate the pig's immune system to develop immunity against specific pathogens, preventing outbreaks and reducing economic losses in the swine industry. Commonly targeted diseases include Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Type 2 (PCV2), and swine influenza. Swine vaccines are essential tools in veterinary medicine, ensuring the sustainability and biosecurity of pig farming operations.
 

Swine Vaccines Market Trends

• The growing consumption of pork is a major trend driving the swine vaccines industry. According to World Population Review’s Pork Consumption Data 2024, the current pork consumption stands at 112.6 kilotons, with an expected rise to 129 kilotons by 2031. As pork demand rises globally, particularly in regions like Asia-Pacific, Europe, and North America, swine producers are compelled to maintain healthy and productive herds.
   
• Diseases such as PRRS, ASF, and PCV2 pose significant threats to swine health, impacting growth rates, reproductive efficiency, and meat quality. To prevent these diseases and meet market demands, producers are increasingly adopting vaccination programs.
   
• Additionally, consumer concerns about food safety and animal welfare are growing, emphasizing the need for healthier herds. Vaccinated animals are less likely to transmit diseases, resulting in safer meat products. Thus, this trend further supports the adoption of swine vaccines, driving market growth.
   

Swine Vaccines Market Analysis

Based on product, the market is segmented into inactivated vaccines, live attenuated vaccines, recombinant vaccines, subunit vaccines, toxoid vaccines, and other products. The inactivated vaccines segment accounted for USD 568.4 million in 2023 in the global market.
 

• The proven track record of inactivated vaccines in preventing diseases like porcine reproductive and respiratory syndrome, swine influenza, erysipelas, foot-and-mouth disease among others contributes to their widespread acceptance and trust among farmers and veterinarians.
   
• Additionally, inactivated vaccines tend to cause fewer side effects and adverse reactions, increasing their acceptance and further contributing to their dominant market share.
   

Based on disease type, the swine vaccines market is classified into porcine reproductive and respiratory syndrome (PRRS), porcine circovirus type 2 (PCV2), mycoplasma hyopneumoniae, classical swine fever (CSF), swine influenza, erysipelas, foot-and-mouth disease (FMD), African swine fever (ASF), porcine parvovirus, and other disease types. The porcine reproductive and respiratory syndrome (PRRS) segment held highest market share of 17.8% in 2023.
 

• PRRS is one of the most widespread and economically damaging diseases affecting swine herds globally. Its high prevalence necessitates effective vaccination programs to control and prevent outbreaks, driving significant demand for PRRS vaccines.
   
• PRRS severely affects pig productivity, causing issues like abortions in pregnant sows, stillbirths, and weak piglets. Vaccination is essential to maintain herd health and productivity, ensuring consistent and high-quality pork production.
   
• These factors collectively aid in driving the growth of porcine reproductive and respiratory syndrome segment in market.

Based on end-user, the swine vaccines market is categorized into veterinary hospitals & clinics, swine farms, and research institutes. The veterinary hospitals & clinics segment dominated the global market and is poised to grow at 5% CAGR.
 

• Veterinary hospitals and clinics hold the highest market share in the swine vaccine market due to their professional expertise and trust. Farmers and swine producers rely on veterinarians for effective disease management and prevention, ensuring high vaccine uptake.
   
• These facilities have access to the latest and most advanced vaccines, ensuring swine are protected against emerging and evolving diseases. The ability to provide cutting-edge vaccination solutions enhances the appeal of veterinary hospitals and clinics as primary vaccination providers, driving segment growth.

In 2023, the North American swine vaccines market was valued at USD 633.6 million and is expected to grow at a CAGR of 5.1% from 2024 to 2032.
 

• North America boasts advanced veterinary infrastructure, including well-equipped hospitals, clinics, and research facilities. This robust infrastructure supports efficient vaccine distribution, administration, and monitoring, ensuring high vaccination coverage and effectiveness.
   
• Furthermore, the region faces a high prevalence of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS) and Porcine Circovirus Type 2 (PCV2). The need to control these economically damaging diseases drives substantial growth of this market.
   

The U.S. swine vaccines market, which accounted for USD 583.6 million in 2023, is projected to reach USD 893.6 million by 2032.
 

• The U.S. is one of the largest pork producers and consumers globally. For instance, according to National Pork Board, the U.S. produces 11% of the world’s pork.
   
• This high demand for pork necessitates maintaining healthy swine herds. Producers adopt comprehensive vaccination programs to ensure consistent and high-quality meat production, driving swine vaccine market growth.
   

The swine vaccines market in China is set for remarkable growth in the coming years.
 

• There is a trend towards larger-scale swine farming operations in China, which are better equipped to implement comprehensive biosecurity measures and vaccination protocols.
   
• Modernized farms prioritize disease prevention to ensure consistent pork production, fueling the growth of market in China.
   

India is anticipated to grow at a considerable rate in the global swine vaccines market.
 

• India emerged as the 46th largest pig meat exporter globally in 2022, with exports totaling USD 3.75 million, as per OEC data. Key destinations for Indian pig meat shipments encompass Bhutan, Maldives, and Tanzania.
   
• As India strengthens its capabilities in swine vaccine production and disease management, there are potential export opportunities to neighboring countries and global markets. This enhances the market potential for Indian swine vaccine manufacturers, driving overall growth in the industry.
   

Swine Vaccines Market Share

The market is characterized by a competitive landscape with several key players vying for market share. Companies such as Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco, and Merck & Co., Inc. are prominent in the market, leveraging extensive R&D investments to develop advanced vaccines. These companies focus on expanding their product portfolios to address a wide range of swine diseases, including Porcine Reproductive and Respiratory Syndrome (PRRS), Swine Influenza, and Foot-and-Mouth Disease (FMD).
 

Swine Vaccines Market Companies

Prominent players operating in the swine vaccines industry include:

• Biogenesis Bago
• Bioveta, a.s.
• Boehringer Ingelheim International GmbH
• Ceva Sante Animale
• Elanco Animal Health Incorporated
• HIPRA
• Indian Immunologicals Limited
• Merck & Co., Inc.
• Phibro Animal Health Corporation
• Vaxxinova
• Virbac
• Zoetis Inc.
   

Swine Vaccines Industry News:

• In March 2024, Merck Animal Health announced approval from the U.S. Department of Agriculture (USDA) for SEQUIVITY with Microsol Diluvac Forte (MDF) adjuvant prescription vaccine for use in gilts and sows. This strategic approval helped the company to broaden its product portfolio.
   
• In June 2023, Merck Animal Health launches 3-in-one swine vaccine. The 3-in-one vaccine that controls for diseases Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae and Lawsonia intracellularis. This strategic launch helped the company to meet the demand for comprehensive disease control solutions, consolidating its presence in the industry.
   

The swine vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Inactivated vaccines
• Live attenuated vaccines
• Recombinant vaccines
• Subunit vaccines
• Toxoid vaccines
• Other products

Market, By Disease Type

• Porcine reproductive and respiratory syndrome (PRRS)
• Porcine circovirus type 2 (PCV2)
• Mycoplasma hyopneumoniae
• Classical swine fever (CSF)
• Swine influenza
• Erysipelas
• Foot-and-Mouth disease (FMD)
• African swine fever (ASF)
• Porcine parvovirus
• Other disease types

Market, By End-user

• Veterinary hospitals & clinics
• Swine farms
• Research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa